Reinaldo Diaz, who also serves on the Board
of Directors of Berkeley Heart Labs, Inc., and advanced cardiovascular
testing and e-healthcare company, has previously worked with a broad
range of healthcare companies. His experience ranges from development
stage companies to mature multinational pharmaceutical companies. He
has particular expertise in the funding of novel, pharmaceutical compounds
developed by emerging biopharmaceutical companies. In the past, he has
served on the Board of Directors of such companies as Alkermes, Inc.,
Amgen Development Corporation, Genentech Development Co., and Genzyme
Development Co.
Five years ago, Reinaldo Diaz founded the Diaz & Altschul Group,
LLC, (D & A Group), a merchant bank, focused on the healthcare industry.
The D & A Group, through its subsidiaries, Diaz & Altschul Advisors,
LLC and Diaz & Altschul Capital, LLC, a member of the National Association
of Securities Dealers, has provided investment banking services as well
as asset management advice to its clients in the healthcare industry.
Diaz & Altschul Advisors, LLC in the investment advisor to the Delta
Funds, a group of private investment funds with approximately $100 million
in assets focused on healthcare and life sciences companies. Since the
inception of the D & A Group, Reinaldo Diaz and his partners have
structured over $325 million on investments in the healthcare industry.
Frank R. Ruderman
Frank Ruderman is the Chief Executive Officer,
Chairman of the Board, and a Managing Partner of Tenex Greenhouse Ventures.
Additionally, Mr. Ruderman is the Chairman and CEO of Berkeley HeartLab.
He is also a founder of Tenex Medical Investors, an organization of
angel investors with an exclusive focus in the life sciences. He serves
on the Board of Directors of Watergate Software, and is also a member
of the Global Advisory Board of the Asian Business Association.
Mr. Ruderman had been a consultant and a director of Genomyx from its
founding at Genentech with Human Genome Project funding, later acting
as President/CEO and CFO. Genomyx was sold to Beckman Instruments. He
founded and acted President, COO and a Director of Physiometrix, which
went public at a $60 million valuation. Mr. Ruderman also helped to
found two additional medical device companies, Intella Interventional
(private) and Cardiac Pathways (public at a $200 million valuation)
as spin-outs of Physiometrix. Mr. Ruderman served as a Board member,
President, COO and CFO of American Bionetics, which saw revenue growth of
5x and its stock price increased to a high of 8x, the IPO price. The
Company was sold to BioGenex after finalizing two acquisitions and completing
joint ventures with Millipore and Dupont. He served as a member of the
Board and the first President/CEO of Mast Immunosystems, which was sold
to Hitachi. Before that, Mr. Ruderman served in various domestic and
international corporate executive positions with Pfizer Pharmaceuticals,
Pfizer Diagnostics and Millipore.
Mr. Ruderman has an M.B.A. from the Amos Tuck School of Business at
Dartmouth College, an M.A. in vascular physiology from Boston University,
and a B.S. in biology from Tufts University.
Fred Middleton
Fred Middleton has over twenty years experience
in the biotechnology and biomedical industries in both corporate management
and as an institutional investor. Mr. Middleton joined Dr. McNeil in
late 1987 as a General Partner at Sanderling. Since 1987, Mr. Middleton
has focused on venture capital investments in the corporate development
of early-stage biomedical companies at Sanderling, serving as a founder,
management team member and director of numerous start-up ventures in
the Sanderling portfolio. Over the last several years, he has played
active management roles as Chairman, CEO or Director of a number of Sanderling
portfolio companies, including DepoTech (Skyepharma), Regeneron, Vical,
Stereotaxis, and Genteric.
In 1984, Mr. Middleton founded Morgan Stanley Ventures, serving as managing
general partner of an institutional fund raised to sponsor R&D funding
arrangements at leading technology companies in the biomedical sciences
and information technology fields.
Mr. Middleton began his career as a consultant for McKinsey & Company's
San Francisco office and was also a Vice President of Chase Manhattan
Bank in New York. In 1978, Mr. Middleton joined the founders of biotechnology
pioneer Genentech, Inc., to become part of the original management team,
and served as Vice President of Finance, Administration, Corporate Development,
as well as Chief Financial Officer. While at Genentech, Mr. Middleton
completed over $200 million in corporate partnering and institutional
funding transactions, including the Company's initial public offering
in 1980.
Mr. Middleton earned a B.S. in chemistry from the Massachusetts Institute
of Technology in 1971 and an M.B.A with distinction from Harvard Business
School in 1973.